Comparison of clinical and microbiological response to treatment of Clostridium difficile-associated disease with metronidazole and vancomycin
- PMID: 18491964
- DOI: 10.1086/588293
Comparison of clinical and microbiological response to treatment of Clostridium difficile-associated disease with metronidazole and vancomycin
Abstract
Background: There have been recent reports of frequent treatment failure associated with the use of metronidazole for treatment of Clostridium difficile-associated disease. We tested the hypothesis that treatment failure with metronidazole is associated with a suboptimal microbiological response in comparison with that of vancomycin.
Methods: We conducted a 9-month prospective observational study of patients with C. difficile-associated disease. Cox proportional hazards models were used to compare metronidazole-treated and vancomycin-treated patients in terms of time to resolution of diarrhea and time to reduction of C. difficile in stool to an undetectable level.
Results: Of 52 study patients with C. difficile-associated disease, 34 (65%) received initial therapy with oral metronidazole, and 18 (35%) received initial therapy with oral vancomycin. Diarrhea resolved in >90% of patients who completed 10 days of treatment with either agent. However, vancomycin-treated patients were more likely to develop undetectable levels of C. difficile (adjusted hazard ratio, 3.99; 95% confidence interval, 1.41-11.3;P = .009) and to have resolution of diarrhea (adjusted hazard ratio, 4.17; 95% confidence interval, 1.53-11.40;P = .005) during the first 5 days of therapy. Ten metronidazole-treated patients (29%) had their treatment changed to oral vancomycin because of persistent symptoms. Seven (70%) of these 10 patients had <1 log reduction in C.difficile concentration; however, only 4 had completed > or = 6 days of metronidazole treatment at the time of the treatment change.
Conclusion: In an observational study with a limited number of subjects, a majority of patients with C. difficile-associated disease responded to therapy with metronidazole or vancomycin. Failure with metronidazole treatment may be attributable to a slower and less consistent microbiological response than that with oral vancomycin treatment.
Comment in
-
Decreased effectiveness of metronidazole for the treatment of Clostridium difficile infection?Clin Infect Dis. 2008 Jul 1;47(1):63-5. doi: 10.1086/588294. Clin Infect Dis. 2008. PMID: 18491959 No abstract available.
Similar articles
-
A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity.Clin Infect Dis. 2007 Aug 1;45(3):302-7. doi: 10.1086/519265. Epub 2007 Jun 19. Clin Infect Dis. 2007. PMID: 17599306 Clinical Trial.
-
Update on Clostridium difficile-induced colitis, Part 2.Am J Hosp Pharm. 1994 Aug 1;51(15):1892-901; quiz 1958-9. Am J Hosp Pharm. 1994. PMID: 7942924 Review.
-
Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole.Clin Infect Dis. 2005 Jun 1;40(11):1586-90. doi: 10.1086/430311. Epub 2005 Apr 25. Clin Infect Dis. 2005. PMID: 15889354
-
Outcomes of Clostridium difficile-associated disease treated with metronidazole or vancomycin before and after the emergence of NAP1/027.Am J Gastroenterol. 2007 Dec;102(12):2781-8. doi: 10.1111/j.1572-0241.2007.01539.x. Epub 2007 Sep 26. Am J Gastroenterol. 2007. PMID: 17900327
-
Past, present, and future therapies for Clostridium difficile-associated disease.Ann Pharmacother. 2006 Dec;40(12):2155-63. doi: 10.1345/aph.1H332. Epub 2006 Dec 5. Ann Pharmacother. 2006. PMID: 17148650 Review.
Cited by
-
Epidemiology and Outcomes of Recurrent C Difficile Infection Among Hematopoietic Cell Transplant Recipients: A Single-center, Retrospective 10-year Study.Open Forum Infect Dis. 2024 Oct 1;11(10):ofae570. doi: 10.1093/ofid/ofae570. eCollection 2024 Oct. Open Forum Infect Dis. 2024. PMID: 39450393 Free PMC article.
-
Effective treatment of Clostridioides difficile infection improves survival and affects graft-versus-host disease: a multicenter study by the Polish Adult Leukemia Group.Sci Rep. 2024 Mar 11;14(1):5947. doi: 10.1038/s41598-024-56336-3. Sci Rep. 2024. PMID: 38467719 Free PMC article.
-
Clostridioides difficile infection: history, epidemiology, risk factors, prevention, clinical manifestations, treatment, and future options.Clin Microbiol Rev. 2024 Jun 13;37(2):e0013523. doi: 10.1128/cmr.00135-23. Epub 2024 Feb 29. Clin Microbiol Rev. 2024. PMID: 38421181 Review.
-
Proton pump inhibitor-induced gut dysbiosis and immunomodulation: current knowledge and potential restoration by probiotics.Pharmacol Rep. 2023 Aug;75(4):791-804. doi: 10.1007/s43440-023-00489-x. Epub 2023 May 4. Pharmacol Rep. 2023. PMID: 37142877 Free PMC article. Review.
-
Factors influencing environmental sampling recovery of healthcare pathogens from non-porous surfaces with cellulose sponges.PLoS One. 2022 Jan 13;17(1):e0261588. doi: 10.1371/journal.pone.0261588. eCollection 2022. PLoS One. 2022. PMID: 35025906 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
